LEXINGTON, Mass., April 6, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) announced today that new data from a Phase 2 trial testing the Prophage G-200 vaccine (HSPPC-96; vitespen) in recurrent ...
Prophage is being developed for the treatment of patients with newly diagnosed glioblastoma multiforme (GBM.V). Results from the study revealed that the median overall survival of approximately 24 ...
Agenus Inc. AGEN announced that it has entered into a clinical trial collaboration with the National Cancer Institute (NCI) to evaluate its personalized autologous vaccine candidate, Prophage ...
A phage is a virus that invades a bacterial cell. While harmless to human cells, phages are potentially deadly to bacteria since many phages enter a cell in order to hijack its machinery in order to ...
PHAGERIARUS ® development project is focused on acquiring bacteriophage-derived proteins that can serve as Immune Regulators (IR). The ultimate goal is to develop phage-based immunotherapeutics ...
LEXINGTON, Mass., May 18, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) today announced that new data from a Phase 2 trial testing the Prophage G-200 vaccine (HSPPC-96; vitespen) in recurrent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results